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Brief description – “Novelty and Impact” 64 
Head and neck cancer (HNC) is a complex and difficult-to-treat malignancy that leads to 65 
severe disabilities and high mortality. We investigated if, after major improvements in 66 
diagnosis and therapeutic modalities, HNC survival has increased in Europe, and what 67 
are the main determinants of outcome. We found that survival from HNC remains low in 68 
Europe and, alongside with late stage at diagnosis, older age at diagnosis and smoking 69 
are strong predictors of outcome.  70 
 71 
Abstract 72 
Head and neck cancer (HNC) is a preventable malignancy that continues to cause 73 
substantial morbidity and mortality worldwide. Using data from the ARCAGE and Rome 74 
studies, we investigated the main predictors of survival after larynx, hypopharynx and 75 
oral cavity (OC) cancers. We used the Kaplan-Meier method to estimate overall survival, 76 
and Cox proportional models to examine the relationship between survival and 77 
sociodemographic and clinical characteristics. 604 larynx, 146 hypopharynx and 460 OC 78 
cancer cases were included in this study. Over a median follow-up time of 4.6 years, 79 
nearly 50% (n=586) of patients died. Five-year survival was 65% for larynx, 55% for OC, 80 
and 35% for hypopharynx cancers. In a multivariable analysis, we observed an increased 81 
mortality risk among older (≥71 years) vs. younger (≤50 years) patients with 82 
larynx/hypopharynx combined (LH) and OC cancers [HR=1.61, 95% CI 1.09–2.38 (LH) 83 
and HR=2.12, 95% CI 1.35–3.33 (OC)], current vs. never smokers [HR=2.67, 95% CI 84 
1.40–5.08 (LH) and HR=2.16, 95% CI 1.32–3.54 (OC)], and advanced vs. early stage 85 
disease at diagnosis [IV vs. I, HR=2.60, 95% CI 1.78–3.79 (LH) and HR=3.17, 95% CI 86 
2.05–4.89 (OC)]. Survival was not associated with sex, alcohol consumption, education, 87 
oral health, p16 expression, presence of HPV infection, or body mass index 2 years 88 
before cancer diagnosis. Despite advances in diagnosis and therapeutic modalities, 89 
survival after HNC remains low in Europe. In addition to the recognized prognostic effect 90 
of stage at diagnosis, smoking history and older age at diagnosis are important 91 
prognostic indicators for HNC.  92 
  93 
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Introduction 94 
Head and neck cancer (HNC) is mostly comprised of oral cavity, oropharynx, 95 
hypopharynx, and larynx tumors. When taken together, HNC represents the 5th most 96 
common malignancy in males in the high-income countries, with a lower incidence 97 
among females (male to female ratio varies from 2:1 to 4:1).1 Over 90% of cases are 98 
squamous cell carcinomas.2 HNC can be cured if the tumor is diagnosed at early stage 99 
and limited to the head and neck region. However, prognosis is very poor when HNC is 100 
diagnosed at later stages with metastatic or recurrent disease. A decision between 101 
aggressive multimodality and function-preserving treatment should be based on patient’s 102 
health and comorbidities, and on the extent to which therapy may affect the patient’s 103 
quality of life.3  104 
 Tobacco exposure (including active and smokeless tobacco use) and alcohol 105 
consumption are well-established risk factors for HNC.4 Human Papillomavirus (HPV) 106 
infection is an additional independent risk factor for oropharynx cancer. Studies have 107 
shown that HPV-related HNC is genetically and biologically different from smoking-108 
associated HNC, with HPV-related HNC demonstrating improved clinical outcomes.3 109 
HPV positive oropharynx cancer patients commonly have greater survival than HPV 110 
negative cases.5-7 However, the same HPV causal and prognostic associations have not 111 
been observed for larynx, hypopharynx, or oral cavity cancer where HPV infections are 112 
rare.8  113 
Stage at diagnosis has been considered one of the strongest predictors of survival 114 
among patients with HNC,9 whereas the role of smoking and alcohol on survival remains 115 
controversial. Robust epidemiological data may help to identify modifiable prognostic 116 
factors and guide cancer prevention programs aimed to reduce the burden of HNC 117 
worldwide.10 In this study we focused on the determinants of survival from larynx, 118 
hypopharynx, and oral cavity cancers in Europe. A separate study has examined survival 119 
from oropharynx cancer including the role of HPV.11  120 
121 
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Patients and methods 122 
Patients 123 
Data was obtained from 14 centers located in 9 European countries. Thirteen centers 124 
were participants of the ARCAGE* case-control study12 as follows: Czech Republic 125 
(Prague), Germany (Bremen), Greece (Athens), Italy (Aviano, Padova, and Turin), 126 
Ireland (Dublin), Norway (Oslo), United Kingdom (Glasgow, Manchester, and Newcastle), 127 
Spain (Barcelona), and Croatia (Zagreb). The remaining data were obtained from a case-128 
control study in Rome.13 The recruitment of cases was performed from 2002 to 2005 for 129 
the ARCAGE study (n=1,066) and from 2003 to 2011 for the Rome study (n=144). 130 
Details of the ARCAGE and Rome projects can be found elsewhere.12,13  131 
 Cases eligible for inclusion in our study were all patients with a primary squamous 132 
cell carcinoma of the larynx, hypopharynx or oral cavity confirmed by histology or 133 
cytology. We included the following topography codes from the International 134 
Classification of Diseases for Oncology, 3rd edition (ICD-O-3)14: C320-C32.9 for larynx, 135 
C12.9 and C13.0-C13.9 for hypopharynx, and C00.3-C00.9, C02.0-C02.3, C03.0-C03.9, 136 
C04.0-C04.9, C05.0, and C06.0-C06.9 for oral cavity cancers. Following a standard 137 
protocol, participants underwent an identical questionnaire-based interview within 6 138 
months of diagnosis in order to obtain sociodemographic information, complete lifetime 139 
smoking and alcohol histories, dietary habits, dental health and care, and education level 140 
attained. Biological samples (blood and/or tumor blocks) were also collected. Data on 141 
stage at diagnosis, overall treatment, and clinical outcomes were subsequently obtained 142 
from population-based registries, medical records, linkage with regional or national death 143 
index, as well as doctor’s contact. Participants were followed from the date of diagnosis 144 
to the date of death, loss to follow-up or end of study (31st December 2011), whichever 145 
occurred first. Patient’s follow-up was performed once from 2012 to 2015 to obtain last 146 
known vital status (alive, death, or lost to follow-up) and date of last contact.  147 
 148 
Sociodemographic, clinical and lifestyle variables  149 
The sociodemographic, clinical and lifestyle variables were classified as follows. Age at 150 
diagnosis was categorized in 4 groups (≤50, 51–60, 61–70, and ≥71 years). Tumor stage 151 
at diagnosis was classified in stage I to IV based on the TNM system of the American 152 
Joint Commission on Cancer (AJCC) Staging Manual, 6th edition.15 Smoking was 153 
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examined in 3 different ways: overall history (never, former or current smokers), duration 154 
(never, 1–9, 10–19, 20–29, 30–39 and ≥40 years), or intensity (number of pack of 155 
cigarettes per year: never, <20, 20–39, 40–59, ≥60). Smokers were individuals who used 156 
any tobacco product (estimated based on cigarette equivalents) at least once a week for 157 
one year. Alcohol consumption was also examined in 3 ways: overall history (never, 158 
former or current drinkers), duration (never, 1–9, 10–19, 20–29, 30–39 and ≥40 years), 159 
and intensity (number of drinks per day: <5 or ≥5). Information on overall smoking and 160 
alcohol histories were obtained from all centers, whereas Rome did not have information 161 
on duration and intensity of these variables. Therefore, overall histories were included in 162 
the main models and separate models, excluding Rome cases, were performed to 163 
examine the effect of smoking and alcohol duration and intensity on survival, and were 164 
included in the supplementary materials (Table S1). 165 
 Education was categorized as level of education attained by the time of diagnosis: 166 
primary school, secondary school or university degree. Body mass index (BMI, kg/m2) 167 
was examined using self-reported height and weight 2 years before cancer diagnosis, 168 
which decreases the probability that low BMI is secondary to cancer development.16 BMI 169 
was classified according to the World Health Organization into 4 categories: underweight 170 
(<18.5), normal weight (18.5–24.9), overweight (25.0–29.9) and obese (≥30.0). Dental 171 
care and oral hygiene scores were created and classified as good, moderate, and poor 172 
as described elsewhere.17  173 
 Binary variables were sex (male/female) and the HPV tumor markers HPV16 DNA 174 
and p16 protein expression (positive/negative). HPV16 DNA genotyping was done using 175 
the type-specific E7 polymerase chain reaction bead-based multiplex assay (TS-E7-176 
MPG, IARC, Lyon, France) as described elsewhere.17 The qualitative assessment of 177 
antigen p16INK4A was performed by immunohistochemistry, using the CINtec Histology kit 178 
according to the manufacturer’s instructions (www.mtmlabs.com). P16 expression was 179 
scored based on the intensity and the proportion of nuclear and cytoplasmic stained 180 
cells, and was considered positive when the combined score was equal to 4 or higher. 181 
Studies have shown that combined p16 expression and HPV16 DNA testing are needed 182 
to predict outcome for HNC.18 We examined p16 expression alone and combined with 183 
HPV16 DNA as follow: p16 (–) DNA (–), p16 (+) DNA (–), p16 (+) DNA (+), and p16 (–) 184 
DNA (+). In addition to the variables above, we provided a descriptive analysis on 185 
relapse occurrence and overall treatment.  186 
 187 
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Statistical analyses 188 
We used the Kaplan-Meier method to estimate 2-, 5- and 8-year overall (all-cause) 189 
survival, and used the log-rank test to examine differences in survival across strata of 190 
each variable. Overall survival is presented by anatomic site and, sample size allowing, 191 
by tumor subsite (glottis vs. supraglottis, tongue vs. other regions of the mouth, as well 192 
as pyriform sinus and other hypopharynx regions).  193 
 Multivariable Cox regression models were used to obtain the hazard ratios (HRs) 194 
of death and corresponding 95% confidence intervals (CI). We used the likelihood ratio 195 
test as an overall significance test for the association of each independent variable with 196 
the hazard ratio of death. We tested the proportional hazard (PH) assumption by 197 
examining log-log survival plots, and confirmed the results by using Schoenfeld’s global 198 
test. The PH assumption was met for all variables in the multivariable models. We 199 
included in the multivariable models the variables with a priori hypothesized or previously 200 
observed associations with survival (sex, age and stage at diagnosis, smoking and 201 
alcohol histories, BMI 2 years before diagnosis, education level, and dental care) and 202 
additionally adjusted for year of diagnosis. A separate model was performed to examine 203 
the association between HPV tumor markers and survival. 204 
 Given the modest number of hypopharynx cases, they were pooled with larynx 205 
cases for the multivariable analysis. When we performed separate Cox models, we 206 
observed the same pattern of associations for both larynx and hypopharynx cases, but 207 
with larger confidence intervals and p-values for hypopharynx cases due to the smaller 208 
sample size. Cases from Rome did not provide data on education, BMI pre-diagnosis 209 
and oral health. Missing data were handled by including them as “unknown” categories in 210 
the multivariable models (omitted in the tables). A complete analysis where missing data 211 
were excluded was also conducted, and similar results were obtained. We tested for 212 
interactions between tumor sites and each variable and found no significant interaction. 213 
Statistical analyses were performed using Stata 14 software (StataCorp, College Station, 214 
TX, USA), and a 2-sided p-value of less than 0.05 was considered statistically significant. 215 
 216 
Ethics approval 217 
The ARCAGE study was approved by the Ethical Review Board of the International 218 
Agency for Research on Cancer (IARC), as well as the respective local boards in the 219 
individual participating centers. The Rome study was approved by the ethical committee 220 
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of Fondazione Policlinico Universitario “A. Gemelli”. All participants provided written 221 
informed consent for their participation in the study.  222 
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Results  223 
A total of 604 (50%) larynx, 146 (12%) hypopharynx and 460 (38%) oral cavity cancer 224 
cases were included in this study. The sociodemographic and clinical characteristics of 225 
patients are summarized by anatomic site in Table 1. Overall, most of patients were 226 
males (82%), ever smokers (91%), and ever drinkers (93%), had a median age at 227 
diagnosis of 60 years, and were diagnosed with advanced stage disease (55% stages III 228 
or IV vs. 45% stages I or II). 229 
 230 
Overall survival  231 
The median follow-up time was 4.6 years. Of 1,210 patients, nearly half (n=586) died 232 
over the course of follow-up. Five-year survival was 65% for larynx (95% CI 61–69), 55% 233 
for oral cavity (95% CI 50–60) and 35% for hypopharynx (95% CI 27–43) cancers 234 
(Tables 2A & 2B, Figure1A). When an adequate sample size was available, survival was 235 
also examined by anatomic subsite. Based on the log-rank test, we observed that 5-year 236 
survival was higher among patients with glottic vs. supraglottic cancer (77% vs. 58%), 237 
and for those with tumor of the tongue vs. other regions of the mouth (63% vs. 50%). 238 
There was no evidence of difference in survival between patients with cancer of the 239 
pyriform sinus and other hypopharynx regions (Figures 1B-D). 240 
 For all anatomic sites, we found strong evidence of an association between worse 241 
survival and smoking history (former or current smoker) (Tables 2A & 2B,) or advanced 242 
stage disease at diagnosis (Tables 2A & B, Supplementary Figure S1). Among oral 243 
cavity cancer patients, we also found associations of lower survival with older age at 244 
diagnosis, male sex, lower level of education, and low BMI 2 years before cancer 245 
diagnosis). There was no evidence of survival differences by p16 protein expression 246 
alone or combined with HPV testing for any cancer site (Table 2A & 2B). Survival did not 247 
vary by cancer center or country (data not shown). 248 
 249 
Hazard ratio of death 250 
In a multivariable Cox regression analysis, in which all variables were mutually adjusted 251 
for, we found, among larynx/hypopharynx cases, an increased risk of death for 252 
hypopharynx vs. larynx cancer (HR=2.29, 95% CI 1.79–2.94), older compared to 253 
younger patients (≥71 vs. ≤ 50 years, HR=1.61, 95% CI 1.09–2.38), current vs. never 254 
smokers (HR=2.67, 95% CI 1.40–5.08) and advanced vs. early stage disease at 255 
diagnosis (IV vs. I, HR=2.60, 95% CI 1.78–3.79). Likewise, among oral cavity cancer 256 
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patients, we observed an increased risk of death for older compared to younger patients 257 
(≥71 vs. ≤ 50 years, HR=2.12, 95% CI, HR=1.35–3.33; and 61–70 vs. ≤ 50 years, 258 
HR=1.65, 95% CI 1.12–2.44), current vs. never smoker (HR=2.16, 95% CI 1.32–3.54), 259 
and for those with advanced vs. early stage at diagnosis (IV vs. I, HR=3.17, 95% CI 260 
2.05–4.89) (Table 3). We did not find significant associations between the risk of death 261 
and sex, dental care or BMI 2 years pre-diagnosis.  262 
 In separate analyses, when we used the number of packs of cigarettes smoked 263 
per year or duration of smoking instead of overall smoking history (Rome cases 264 
excluded), similarly strong associations were found. For instance, larynx/hypopharynx 265 
patients who smoked ≥20 cigarette pack years had approximately 3 times higher risk of 266 
death than never smokers. Likewise, for oral cavity cancer, patients who smoked ≥20 267 
cigarette pack years had a risk of death about 2.5 times higher than never smokers. 268 
(Supplementary Table S1) When we examined alcohol duration and intensity, we also 269 
did not find evidence of an association between the risk of death and alcohol 270 
consumption (Supplementary Table S1). There was no evidence of an association 271 
between the risk of death and p16 expression, whether examined alone or combined with 272 
HPV16 DNA testing (Figure 2, Supplementary Table S2).  273 
 274 
Descriptive analysis 275 
Data on relapse was available for approximately 80% of cases. Out of 973 patients, 341 276 
(35%) relapsed. Higher incidence of relapse was observed among patients with 277 
hypopharynx (46%), followed by oral cavity (38%) and larynx (30%) cancers (p=0.002). 278 
After excluding cases to whom relapse occurred less than 90 days from diagnosis 279 
(n=49), we observed that the majority of patients (n=194, 72%) relapsed within 2 years of 280 
HNC diagnosis, whereas 19% (n=52) and 9% (n=25) relapsed within >2 to 5 years and 281 
>5 to 10 years respectively (Supplementary Figure S2). Time to relapse did not differ 282 
significantly by anatomic site. 283 
 Overall information on type of treatment was available for approximately 97% of 284 
cases. Surgery was performed in most of patients (74%), alone (34%) or combined with 285 
radiotherapy (28%), chemotherapy (1%), or both (11%). About 12% of patients received 286 
radiotherapy alone, 10% received chemotherapy and radiotherapy, and 1% received 287 
chemotherapy alone. For about 2% of patients no type of treatment was reported. 288 
 289 
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Discussion 290 
Our results reveal that survival from head and neck cancer remains low in Europe. 291 
Except for patients with tumors of the glottis, 8-year survival was lower than 50% for all 292 
tumor sites and subsites. In the multivariable analyses, the main predictors of survival 293 
were age at diagnosis, stage at diagnosis, smoking history, and anatomic site.  294 
 Age at diagnosis is often considered an independent predictor of outcome for 295 
many types of cancer.19,20 The influence of age on HNC survival remains controversial. In 296 
a recent review, which included surgical, radiation-alone, and chemoradiation studies 297 
from 1980 to 2012, the authors concluded that even though elderly patients may 298 
experience higher treatment-related toxicities than their younger counterparts, there was 299 
not sufficient evidence that survival is worse among older than younger patients (the 300 
majority of the studies investigated overall rather than disease-free or cancer-specific 301 
survival).21 Another study which use data from the Surveillance Epidemiology and End 302 
Results (SEER) program in the United States (US) and estimated overall survival of 303 
patients diagnosed with larynx, tongue or tonsil cancer between 1988 and 1998, 304 
supported these findings.22  305 
In contrast, our findings of increased risk of death among older patients (≥71 years 306 
for larynx/hypopharynx and ≥61 years for oral cavity cancers) support the results of 307 
several population-based studies in Europe and in the US. For instance, a European 308 
study used data from 15 French cancer registries on patients diagnosed with HNC 309 
between 1989 and 1997. The authors found that relative survival (which accounts for 310 
competing causes of death) was consistently lower for elderly compared to younger 311 
patients. The excess mortality among patients aged>75 years was apparent during the 312 
first 3 months and after 3 years of diagnosis, with no significant influence of age between 313 
1 and 3 years after diagnosis.23 Likewise, in a later European study on HNC, relative 314 
survival was lower among elderly (≥ 75 years) vs. younger patients diagnosed from 1999 315 
to 2007.9 In the US, a study from a large university-based cancer registry used data from 316 
1990 to 2005 and found that, after adjusting for potential confounders, patients with HNC 317 
aged ≥70 years at diagnosis had a risk of death about twice as high as that of patients 318 
younger than 70 years.24 Notably, the authors showed that when older patients with 319 
advanced disease (stage at diagnosis III–IV) were treated with multimodality therapy, 5-320 
year overall survival was close to that of younger patients who received similar 321 
therapeutic management. However, older patients who received single-modality 322 
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treatment had dramatically lower 5-year survival than their younger counterparts. Older 323 
age is commonly associated with moderate to severe comorbidities, which may diminish 324 
the patient’s ability to tolerate surgery and intensive cancer adjuvant treatment, such as 325 
radiotherapy and/or chemotherapy.10 Comorbidities such as cardiovascular and 326 
pulmonary diseases in HNC patients are mostly secondary to smoking and excessive 327 
alcohol use. In addition, advanced age is associated with a decline in immune function,25-328 
27 which may not only facilitate cancer progression, but also weaken the host immune 329 
response against cancer.10 Nonetheless, studies suggest that, since cancer is the main 330 
cause of death among elderly patients with advanced HNC, the competing causes of 331 
death likely contribute to a small fraction of the lower survival observed among these 332 
patients.24 The main challenge in the treatment of elderly patients with HNC is to decide 333 
for which patients the benefit of intensive multimodality therapy compensates the risk of 334 
treatment toxicity.  335 
 Stage at diagnosis is widely considered a main determinant of cancer survival and 336 
this is also true for HNC.9 Our results showed that even with the advance on diagnosis 337 
procedures observed in the last decades, the majority of patients (55%) with HNC are 338 
still diagnosed with advanced disease (stage III–IV) in Europe. This proportion is close to 339 
the EUROCARE-5 study,9 which used data from 29 European countries on patients 340 
diagnosed from 1999 through 2007. The authors emphasized that over 54% of patients 341 
were diagnosed with regional or metastatic disease. We found that the risk of death was 342 
approximately 2 or 3 times greater among patients with stage III or IV, respectively, than 343 
those with stage I at diagnosis. While HNC can be often cured when diagnosed at early 344 
stage, late stage disease may be untreatable or involve aggressive multimodality 345 
treatment that often leads to severe physical and psychological disabilities. It has been 346 
reported that HNC have the highest risk of disability and work quitting, together with 347 
central nervous system and hematologic malignancies28 348 
 We observed a strong association between smoking and survival. This association 349 
was significant for all investigated variables (overall smoking history, duration, and 350 
intensity) and highlights the importance of intensifying tobacco prevention and control in 351 
Europe. According to the World Health Organization, smoking kills closely 6 million 352 
people per year, more than HIV/AIDS, malaria and tuberculosis combined. It has been 353 
estimated that this number can increase to over 8 million people by 2030 if more 354 
immediate and severe actions are not taken.29 While some previous studies had shown 355 
negative30,31 or limited32,33 association between smoking and HNC survival, our findings 356 
01 February 2018 
Page 13 of 22 
 
support a large population-based study conducted in Ireland which revealed that smoking 357 
at diagnosis was associated with worse survival.34 The authors highlighted that this 358 
association was stronger among patients who had surgical treatment for their HNC, and 359 
neither chemotherapy nor radiotherapy influenced the effect of smoking on survival. One 360 
relevant question in the clinical setting is whether smoking cessation after cancer 361 
diagnosis can improve prognosis of HNC, for instance decreasing treatment 362 
complications and the risk of relapse or second primary malignancy.35 Post-treatment 363 
smoking history was not available in our study.  364 
 While our results support the influence of smoking on survival from HNC, we did 365 
not find the same association regarding alcohol consumption and survival when we 366 
examined overall alcohol history, duration or intensity. Our findings differ from a US 367 
study36 which found that alcohol consumption pre- and post-diagnosis adversely affected 368 
HNC survival, and highlighted the need for aggressive interventions to help patients to 369 
abstain from or decrease alcohol intake. In another US study,37 which enrolled over 370 
1,000 patients with HNC, about 17% of patients had secondary tumors. Strikingly, 371 
alcohol consumption combined with smoking after diagnosis was found to significantly 372 
increase the risk of secondary tumors among these patients. More studies in Europe are 373 
needed to investigate the association between alcohol pre- and post-diagnosis and HNC 374 
outcomes. 375 
 In our study, HNC prognosis varied significantly by anatomic site, with better 376 
survival for larynx, intermediate for oral cavity, and worse for hypopharynx cancer 377 
patients. These results are consistent with previous survival studies in Europe. For 378 
example, the EUROCARE II study,38 which used data from 17 countries on patients 379 
diagnosed from 1985 to 1989, revealed that overall, 5-year relative survival was 380 
approximately 63% for larynx, 41% for oral cavity, and 22% for hypopharynx cancer, with 381 
wide geographic variations (higher survival in Western than Eastern European countries). 382 
The authors suggested that possible reasons for the observed survival disparities are 383 
late diagnosis, late referral to treatment, and lack of access to effective treatment. The 384 
subsequent EUROCARE-5 study9 showed that 5-year relative survival after larynx 385 
cancer has not improved over time (from 1999–2001 to 2005–2007), whereas survival 386 
improved by 3–5% (absolute difference) for oral cavity, oropharynx, and hypopharynx. 387 
However, 5-year relative survival was still low: 25% for hypopharynx and 45% for oral 388 
cavity cancer patients. Although our results are not directly comparable, the same 389 
survival pattern was observed in our cohort of patients, suggesting no or little 390 
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improvement in the last few decades, despite progresses in diagnosis procedures and 391 
therapeutic management. This finding is concerning and emphasizes the need for 392 
increased healthcare policy aimed at decreasing modifiable risk factors (such as smoking 393 
and alcohol consumption) for HNC occurrence in Europe. 394 
 Curative treatment for HNC is complex and often negatively impacts patient's 395 
quality of life (e.g. causing difficulty to speak, breath, swallow, as well as facial 396 
deformity). Advancements in treatment such as new surgical techniques, the use of 397 
concurrent or alternating chemoradiation, hyperfractionated or accelerated radiotherapy, 398 
and more recently immunotherapy, may improve HNC survival and reduce the burden of 399 
complications secondary to treatment.39 However, improvement in HNC outcomes have 400 
been disappointing. Despite treatment advances, larynx cancer is one of the few types of 401 
cancer in which survival has recently decreased in the US (from 66% during 1975–1977 402 
and 1987–1989 to 63% during 2005–2011).40 It has been postulated that the declining 403 
survival trends are due to changes in treatment toward a nonsurgical (organ 404 
preservation) approach.41,42  405 
 For hypopharynx cancer, a recent population-based study43 using SEER data 406 
showed evidence of increasing survival trends since 1990: 5-year overall survival 407 
improved from 38% during 1973–1989 to 41% during 1990–2003. Through the study 408 
period, there was a trend toward reduced surgical treatment and increased use of 409 
radiation-only therapy. In contrast to what has been observed for larynx cancer in the US, 410 
this study suggests that organ preservation may have a survival benefit for hypopharynx 411 
cancer patients. For oral cavity cancer, surgery remains the first-line treatment,44 while 412 
radiotherapy and lymph node resection are usually performed for advanced stage 413 
disease or for those patients considered ineligible for surgical interventions. 414 
 It has been recognized that approximately 50% of patients with HNC have 415 
substantial weight loss at diagnosis and just before start of therapy in consequence of 416 
cancer symptoms (e.g. dysphagia, odynophagia, and anorexia),45 and this has been 417 
shown to negatively impact survival.46 Therefore, we aimed to investigate whether BMI 2 418 
years before diagnosis also influence survival after HNC. After multiple adjustments, we 419 
did not observe a significant association between the risk of death and underweight, 420 
which may be explained by the small number of patients in this category (fewer than 421 
3.5%). Likewise, overweight or obesity pre-diagnosis was not found to impact survival 422 
among our patients. 423 
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 Finally, when tumor samples were available, we evaluated whether p16 424 
expression alone or associated with HPV16 DNA testing predicts prognosis for non-425 
oropharynx cancers. P16 is a tumor suppressor gene considered a good proxy for HPV 426 
infection in tumors.3 Our results support the lack of an association between survival and 427 
p16 overexpression examined alone, as reported by other authors.47,48 We also did not 428 
find any association with survival when p16 was considered with HPV16 DNA testing. It 429 
is possible that, in our study, the small number of HNC cases that were positive for both 430 
HPV16 DNA and p16 has contributed for the negative association we observed. Further 431 
studies to investigate the prognostic role of these markers on non-oropharynx cancer 432 
outcomes are warranted. 433 
 Our study has several limitations. Since the ARCAGE study was initially designed 434 
to look at risk factors of head and neck cancer, collection of clinical data such as detailed 435 
treatment approach and relapse (including dates of treatment and relapse) were 436 
restricted. Therefore it was not possible to investigate the impact of treatment modality 437 
on survival or relapse. We used self-reported weight and height 2 years before diagnosis, 438 
which may be subject to inaccuracy and bias. However, previous studies have shown 439 
high correlation (r>0.9) between self-reported and measured height, weight and BMI.49,50 440 
Overall, data were missing on stage at diagnosis in about 21% of cases. However, the 441 
strong association we found between stage at diagnosis and survival supports previous 442 
studies and emphasizes the impact of late diagnosis on HNC prognosis. Although Rome 443 
did not have information on certain variables, the data provided by this center were 444 
valuable and the associations we found remained even when these cases were excluded 445 
from the analyses. We also lacked information on comorbidities, performance status, and 446 
treatment complications. Although these data would likely have contributed additional 447 
findings, predictors of HNC outcome such as smoking, stage and age at diagnosis are of 448 
paramount importance and were clearly demonstrated in our study. In addition, the 449 
strengths of the ARCAGE study includes a standard protocol, data from several 450 
European centers with detailed information on smoking and alcohol histories, tumor 451 
histological or cytological confirmation for all patients, as well as blood and tumor 452 
samples for several cases.  453 
 In summary, HNC is a complex malignancy that involves vital anatomic structures, 454 
which make it difficult to treat. Surprisingly, despite the advances in diagnosis and 455 
therapeutic modalities, survival after HNC remains low in Europe. Most patients continue 456 
to be diagnosed with disease at advanced stage, which often requires aggressive 457 
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treatment and may lead to substantial disabilities and psychological disorders, reducing 458 
quality of life among survivors. The association between older age and inferior survival 459 
suggests that treatment should be personalized based on patients’ comorbidities and 460 
tolerability. Importantly, public health efforts in Europe should focus on primary 461 
prevention to deter the initiation of tobacco use, promote smoking cessation, and prevent 462 
excessive alcohol consumption. Furthermore, secondary prevention to detect HNC at an 463 
earlier stage is crucial. 464 
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Figure legends 599 
 600 
Figure 1 - Overall survival from head and neck cancers by: A, anatomic site; B, larynx subsite; C, 601 
hypopharynx subsite; and D, oral cavity subsite, 2002–2011, the ARCAGE study 602 
 603 
Figure 2 - The hazard ratios of death by HPV16 tumor markers among patients with larynx, 604 
hypopharynx, and oral cavity cancers, 2002–2011, the ARCAGE study 605 
 606 
Figure S1: Overall survival from larynx, hypopharynx (combined), and oral cavity cancers by 607 
stage at diagnosis, 2002–2011, the ARCAGE study 608 
 609 
Figure S2: Number of patients with larynx, hypopharynx or oral cavity cancer who relapsed over 610 
time, 2002–2011, the ARCAGE study. Forty-nine patients who relapsed within 90 days since 611 
diagnosis were excluded.  612 
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